Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...

This culminated in a $500m funding cut to mRNA vaccine research funding, impacting around 22 projects being run at the ...

By casting doubt about the promise of mRNA tech, RFK Jr. is slowing progress toward highly effective therapies that could ...

Venture financing for companies developing innovator mRNA-based drugs more than halved from $1.1m in 2023 to $488m in 2024.

A team led by Neil King, a biochemistry professor at the University of Washington School of Medicine, is now exploring a new ...

Secretary of Health and Human ServicesRobert F. Kennedy, Jr.is under constant siege. The political establishment that has ...

Then, demand for its COVID-19 vaccine started to diminish. As hospitals resumed normal operations and anti-vaccine sentiment ...

Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second U.S. company in a week to ...

Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, on Wednesday said it would be challenging to distribute vaccines that use messenger RNA based technology in ...

CureVac's (CVAC) mRNA innovations, strong patent portfolio, and investment potential. Learn the risks and rewards of this biotech stock.

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many ...

It’s that time of year when the leaves are turning golden, there’s a chill in the air and the threat of respiratory viruses ...